Autres

<p>4-Nitrophenyl 5-O-trans-feruloyl-alpha-L-arabinofuranoside is a chromogenic substrate for alpha-L-arabinofuranosidase. Upon hydrolysis, para-nitrophenol is released yielding a yellowish colour. 4-Nitrophenyl 5-O-trans-feruloyl-alpha-L-arabinofuranoside is used in different applications such as the Plant cell wall degradation assays, bacterial enzyme profiling</p>

<p>Crimson-Gal (Crimson-beta-D-galactopyranoside) is a chromogenic indicator for beta-galactosidase activity. The colorless product is cleaved by lactose-utilizing bacteria in liquid media or on agar plates and yields a crimson colored precipitate. Crimson-Gal can also be used as detecting agent for beta-galactosidase activity in reporter gene assays or for identification of positive transformants on agar plates when using the α-complementation approach. Read more in the Application Notes.</p>

<p>Chromogenic substrate targeting lipase, C8 esterase</p>

<p>Applications N-Nitroso-1-(2-methoxyphenyl)piperazine is a reagent used in the preparation of 9-aminoacridine-based agents that impair bovine viral diarrhea virus replication.<br>References Loddo, R. et al.: Bio. &amp; Med. Chem., 26(4), 855-868, (2018)<br></p>

<p>Applications (Z)-4-Hydroxy Tamoxifen O-β-D-Glucuronide is an active metabolite of Tamoxifen (T006000).<br>References Ogura, K. et al.: Biochem. Pharmacol., 71, 1358 (2006); Nishiyama, T. et al.: Biochem. Pharmacol., 63, 1817 (2002); McCague, R. et al.: Biochem. Pharmacol., 39, 1459 (1990);<br></p>

<p>Applications Hydroxyatenolol-d7 is the isotope labelled analog of Hydroxyatenolol (H802480); a metabolite of Atenolol (A790075) which is a cardioselective β-adrenergic blocker, antihypertensive, antianginal, and antiarrhythmic (class II).<br>References Escher, B., et al.: Environ. Sci. Technol., 40, 7402 (2006); Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984)<br></p>

<p>Applications 1,3-Propanediol is a common organic reagent used in the synthesis of polymers and used in industrial organic chemistry for the synthesis of lubricants, foods, medicines and cosmetics.<br>References Sun, Y. et al.: Bioproc. Renew. Res. Commod. Bioprod., 289 (2014);<br></p>

<p>Applications Dehydro Silodosin is an impurity of Silodosin (S465000).<br>References Moriyama., et al.: Eur. J. Pharmacol., 331, 39 (1997), Zhu, J., et al.: Br. J. Pharmacol., 131, 546 (2000),<br></p>

<p>Applications Desmethyl 7-Methoxycarbonyl Nintedanib is an impurity of Intedanib (I666650), which is an indolinone derivative potently blocking VEGF-, PDGF-, and FGF-receptor kinases. it is an indolinone as triple angiokinase inhibitors and an antitumor agent.<br>References Sun, L., et al.: J. Med. Chem., 41, 2588 (1998); Xie, H., et al.: J. Med. Chem., 50, 4898 (2007); Hilberg, F., et al.: Cancer Res., 68, 4774 (2008); Roth, G., et al.: J. Med. Chem., 58, 1053 (2015)<br></p>

<p>Stability Moisture Sensitive<br>Applications 4-​Amino-​2-​fluoro-​N-​methylbenzamide acts as a reagent in the design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists. Also, in the preparation and structure-activity relationship of chiral benzyloxypyridinone derivatives as c-Met kinase inhibitors<br>References Ivachtchenko, A. V., et al.: Eur. J. Med. Chem., 99, 51 (2015); Zhang, D., et al.: Bioorg. Med. Chem. Lett., 23, 2408 (2013)<br></p>

<p>Applications Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.<br>References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);<br></p>

<p>Applications Zafirlukast m-Tolyl Isomer is a positional isomer and impurity of the cysteinyl leukotriene type 1 receptor antagonist, Zafirlukast (D226955).<br>References Krishnaiah, C. et al.: Anal. Chem. Ind. J., 8, 471 (2009); Madhavi, A. et al.: Chromatographia, 70, 233 (2009); Goverdhan, G. et al.: J. Pharmac. Biomed. Anal., 49, 895 (2009);<br></p>

<p>Applications 2-((3-Fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoic acid (cas# 1289942-66-0) is a useful research chemical.<br></p>

<p>Applications Zafirlukast p-Tolyl Isomer is a positional isomer and impurity of the cysteinyl leukotriene type 1 receptor antagonist, Zafirlukast (D226955).<br>References Krishnaiah, C. et al.: Anal. Chem. Ind. J., 8, 471 (2009); Madhavi, A. et al.: Chromatographia, 70, 233 (2009); Goverdhan, G. et al.: J. Pharmac. Biomed. Anal., 49, 895 (2009);<br></p>

<p>Applications (2E)-2-Cyano-3-(3-ethoxy-4-hydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide is an impurity of Entacapone (E558500), a peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. Antiparkinsonian.<br>References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992), Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),<br></p>

<p>Applications (αE)-α-[(3,4-Dihydroxy-5-nitrophenyl)methylene]-β-oxo-1-piperidinepropanenitrile is an impurity of Entacapone (E558500), a peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. Antiparkinsonian.<br>References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992), Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),<br></p>

<p>Applications Substrate specificity of haloalkane dehalogenases.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Koudelakova, T., et al.: Biochem. J., 435, 345 (2011),<br></p>

<p>Stability Hygroscopic<br>Applications A novel active metabolite of the anti-cancer drug Tamoxifen (T006000).<br>References Furr, B., et al.: Pharmacol. Ther., 25, 127 (1984), Leonessa, F., et al.: Cancer Res., 54, 441 (1994), Stearns, V., et al.: Lancet, 360, 1851 (2002), Rae, J., et al.: Pharmacogenetics, 13, 501 (2003), Zheng, Y., et al.: Drug Metab. Dispos., 35, 1942 (2007),<br></p>